Veterinary Hybrid Leverage IsoPet as a revenue entry point to veterinary hospitals and clinics, highlighting FDA veterinary device classification and the non-external beam benefits to persuade adopters seeking targeted canine and feline cancer treatment.

Human Oncology Link Position RadioGel for human tumors as a complementary modality with localized Yttrium-90 radiation, emphasizing reduced skin dose and potential to treat non-resectable or radiation-resistant cancers to attract oncology centers exploring precision brachytherapy.

FDA Validation Capitalize on FDA recognition of IsoPet as a medical device and the associated clear labeling for veterinary indications to build trust with purchasers and streamline procurement conversations in academic and private practice settings.

Revenue Leverage Target high-value institutions impressed by a single technology family (IsoPet and RadioGel) that can generate cross-market trials or collaborations, using existing revenue signals to justify expanded purchasing and potential co-development deals.

Clinical Adoption Highlight the potential for rapid adoption in veterinary settings due to the absence of pre-market approval requirements for veterinary devices, and pursue partnerships with universities and specialty clinics that have pet oncology programs.